Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.